Company Summary:
Quotient Therapeutics, Inc. is a privately held, early-stage company developing a novel genomics platform and therapeutics for diseases with a large unmet need.
Quotient Therapeutics, Inc. was founded by Flagship Pioneering, an innovation enterprise that conceives, creates, resources, and grows first-in-category life sciences companies. Flagship Pioneering has created over 100 groundbreaking companies over the past twenty years, all of which are pioneering novel and proprietary biological, industrial, and engineering approaches to solve major needs in human health and sustainability. These companies include Moderna (MRNA), Seres Therapeutics (NASDAQ: MCRB), Sana Biotechnology (SANA), Axcella Health (AXLA), Indigo Agriculture, Generate Biomedicines, and Tessera Therapeutics.
Position Summary:
We are seeking a Head of Platform that reports to the Chief Science Officer (CSO) and leads a team of scientists. The role involves leadership over Quotient’s lab-based genomics platform, covering the breadth of the development of new experimental capabilities to implementation of high-throughput approaches that maximize operational efficiency and output. Our ideal candidate is someone who thinks strategically, and constantly questions the status quo in search of cutting edge methods and accelerated experimental timelines. The ideal candidate has strong leadership experience, able to lead a diverse team at different levels of seniority. Being collaborative is key – this leader will need to engage and integrate across other teams at Quotient, such as in data science, and target discovery science. This role is based in the vicinity of Cambridge UK and will be primarily based on site. All applicants will require permission to work in the UK.
Key Responsibilities:
- Lead Quotient’s platform technology group, which includes the search and implementation of new technologies, implementation of high-throughput methods, and maximizing data generation throughput and reliability
- Drive the operations of our genomics pipeline, delivering upon the core Somatic Genomics projects at the heart of Quotient’s proprietary target discovery approach
- Lead and manage multiple teams of lab-based scientists, who are responsible for technology development, implementation and operation
- Constantly question the status quo, driving towards cutting-edge solutions in terms of new technologies and operational excellence
- Work directly with the CSO to drive towards major corporate goals, leading Quotient’s technological vision
- Set a high bar for innovation and operations, aiming for rigorous quality
- Collaborate with other leaders at Quotient, constantly seeking ways to innovate and optimize
Qualifications:
- Ph.D. in biology or related discipline with 12+ years of relevant post-Ph.D. experience with an excellent track record of discovering therapeutic targets in a variety of diseases
- Experience developing cutting edge genomics methods, and scaling up for high-throughput data generation, including through the use of automation
- Experience overseeing laboratory operations, with proven track record of operational excellence and knowledge of continuous improvement methods
- Team leadership experience, overseeing team members at different levels of seniority
- Strong written and verbal communication, capable of communicating complex datasets to internal and external stakeholders
- Prior experience developing, owning and delivering visionary technology strategies
About Flagship
Flagship Pioneering is a bioplatform innovation company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $90 billion in aggregate value. Many of the companies Flagship has founded have addressed humanity’s most urgent challenges: vaccinating billions of people against COVID-19, curing intractable diseases, improving human health, preempting illness, and feeding the world by improving the resiliency and sustainability of agriculture. Flagship has been recognized twice on FORTUNE’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies, and has been twice named to Fast Company’s annual list of the World’s Most Innovative Companies. Learn more about Flagship at www.flagshippioneering.com.
Flagship Pioneering and our ecosystem companies are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.
At Flagship, we recognize there is no perfect candidate. If you have some of the experience listed above but not all, please apply anyway. Experience comes in many forms, skills are transferable, and passion goes a long way. We are dedicated to building diverse and inclusive teams and look forward to learning more about your unique background.
Recruitment & Staffing Agencies: Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.
Top Skills
What We Do
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability.
Since its launch in 2000, the firm has applied a unique, hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $30 billion in aggregate value. To date, Flagship is backed by >$3 billion of aggregate capital commitments, of which over $1.5 billion has been deployed toward the founding and growth of its pioneering companies alongside >$10 billion of follow-on investments from other institutions.
The current Flagship ecosystem includes Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Moderna Therapeutics (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS).
